華領醫藥(02552.HK)逆市續漲20%創逾七個月高 完成糖尿病首創新藥臨床試驗
華領醫藥(02552.HK)完成糖尿病首創新藥治療III期臨床試驗,該股連升第五天,承昨天重越牛熊線(5.34元)勢,今天高見6.78元,創七個月高,現造6.59元,逆市續漲20%,成交續增至475萬股,涉資3,125萬元。
華領公布,已完成糖尿病首創新藥Dorzagliatin的III期臨床試驗。在28周開放性治療期內,Dorzagliatin持續顯示出良好的安全性和耐受性,作為2型糖尿病主要標誌的胰島素抵抗指標持續性降低。此外,52周試驗在463名2型糖尿病患者中開展,旨在研究患者接受一天兩次Dorzagliatin 75mg用藥治療的療效和安全性,前24周為隨機雙盲、安慰劑對照治療,用以評估Dorzagliatin的主要療效終點和安全性,後28周則為開放性藥物治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.